TY - JOUR
T1 - Hospital costs of delayed gastric emptying following pancreatoduodenectomy and the financial headroom for novel prophylactic treatment strategies
AU - Francken, Michiel F. G.
AU - van Roessel, Stijn
AU - Swijnenburg, Rutger-Jan
AU - Erdmann, Joris I.
AU - Busch, Olivier R.
AU - Dijkgraaf, Marcel G. W.
AU - Besselink, Marc G.
N1 - Funding Information: Not applicable. Publisher Copyright: © 2021 The Author(s)
PY - 2021/12
Y1 - 2021/12
N2 - Background: Delayed gastric emptying (DGE) is one of the most common complications following pancreatoduodenectomy (PD). In-hospital costs of DGE are unknown as well as the financial headroom for novel prophylactic treatments. This retrospective study aims to estimate the hospital costs of DGE and model the financial headroom per patient for new prophylactic treatment strategies within budget. Methods: Retrospective analysis of a single-center prospective database including patients after PD (2010–2017). In-hospital costs for clinically relevant DGE (ISGPS grade B/C) were calculated by comparing patient groups with and without DGE or other complications. The financial headroom per patient was modelled for potential reductions (0–100%) of empirical DGE baseline risks (15–30%). Results: Overall, DGE was present in 156 (26.9%) of 581 patients after PD. Costs for patients with isolated DGE (n = 90) were €10,295 higher than for patients without complications (n = 333). Costs for patients with other complications including DGE (n = 66) were €9008 higher than for patients with other complications without DGE (n = 92). The financial headroom for a novel prophylactic treatment per patient undergoing PD was €975 per 10% absolute decrease of DGE risk. Conclusion: Hospital costs of DGE after PD are substantial. The financial headroom per patient for new DGE prophylactic treatments can be easily calculated via www.pancreascalculator.com.
AB - Background: Delayed gastric emptying (DGE) is one of the most common complications following pancreatoduodenectomy (PD). In-hospital costs of DGE are unknown as well as the financial headroom for novel prophylactic treatments. This retrospective study aims to estimate the hospital costs of DGE and model the financial headroom per patient for new prophylactic treatment strategies within budget. Methods: Retrospective analysis of a single-center prospective database including patients after PD (2010–2017). In-hospital costs for clinically relevant DGE (ISGPS grade B/C) were calculated by comparing patient groups with and without DGE or other complications. The financial headroom per patient was modelled for potential reductions (0–100%) of empirical DGE baseline risks (15–30%). Results: Overall, DGE was present in 156 (26.9%) of 581 patients after PD. Costs for patients with isolated DGE (n = 90) were €10,295 higher than for patients without complications (n = 333). Costs for patients with other complications including DGE (n = 66) were €9008 higher than for patients with other complications without DGE (n = 92). The financial headroom for a novel prophylactic treatment per patient undergoing PD was €975 per 10% absolute decrease of DGE risk. Conclusion: Hospital costs of DGE after PD are substantial. The financial headroom per patient for new DGE prophylactic treatments can be easily calculated via www.pancreascalculator.com.
UR - http://www.scopus.com/inward/record.url?scp=85108067460&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.hpb.2021.04.025
DO - https://doi.org/10.1016/j.hpb.2021.04.025
M3 - Article
C2 - 34144889
SN - 1365-182X
VL - 23
SP - 1865
EP - 1872
JO - HPB
JF - HPB
IS - 12
ER -